FUJIREBIO

 

 

 AUTO-LIPA 48

 

      Auto-LiPA 48 offers fully automated processing for the complete range of

INNO - LiPA® and INNO - LIA®  tests from hybridization to color development.

Pre-programmed test methods control temperature for the hybridization and 

stringent wash, reagent aspiration and addition, and ensure ease, speed,

and confidence.

 

                       Feature & Benefits

                      Minimum “hands-on” technician time due to:

 

                               Fully automated test performance from hybridization to color development

                               Fully automated temperature control, reagent addition, and aspiration

                               Preprogrammed test methods for INNO-LiPA® and INNO-LIA® products Permanent

                               storage of up to 20 programs

                               Possibility of overnight processing

                               Disposable trays

                               Universal tray for all Innogenetics tests

                               Trays compatible with multi-channel pipettes

                               Automated cleaning procedures

                               Automated pump calibration

 

 

                      Rapid processing

 

                              Washing in less than 3.5 minutes

                              Processing of up to 48 samples per run

                              Results within 2 to 3.5 hours

 

TENDIGO

 

 

                          TENDIGO™ turns daily manual work into automation for low throughput testing volumes.

                          Validated INNO-LIA® and INNO-LIPA® assay protocols on board and open protocol programming.

                          Easy operation, minimum hands-on time, walkaway principle.

                          Dry heating on board for fast and accurate processing; no extra devices needed.

                          Calibration free, self cleaning, ma  intenance and free high quality Qpiptechnology for accurate aspiration and  

                          dispensing. 

 

 
 
 
 

  • When genotyping, be confident. INNO-LiPA® HBV Genotyping is a line probe assay designed to identify hepatitis B virus genotypes A to H by the detection of type-specific sequences in the HBV polymerase gene domain B to C.

  • Minimize treatment failure, Maximize long-term HBV suppression. Line probe assay for simultaneous detection of hepatitis B virus wild-type motif, lamivudine, telbivudine, emtricitabine, adefovir, and entecavir resistance-associated mutations.

  • Detects all known alleles of HLA-A with one amplification and two strips

    INNO-LiPA HLA-A Update is a line probe assay for the molecular typing of human leukocyte antigen (HLA) A alleles at allele group level (A*01–A*80).

  • Detects all known alleles of HLA-B with one amplification and two strips. Bw4/Bw6 ambiguities can be resolved by an additional Bw4-specific amplification and hybridization on one strip.

    INNO-LiPA® HLA-B Update Plus is a line probe assay for the molecular typing of human leukocyte antigen (HLA) B alleles at allele group level (B*07 – B*83).

  • Detects all known alleles of HLA-DQB1 with one amplification and one strip.

    INNO-LiPA® HLA-DQB1 Update is a line probe assay for the molecular typing of human leukocyte antigen (HLA) DQB1 alleles at allelic level (DQB1*02–DQB1*06).

  • Line probe assay, based on the reverse hybridization principle, designed for the identification of 28 different genotypes of the human papillomavirus (HPV) by detection of specific sequences in the L1 region of the HPV genome. The assay uses the proven SPF10* primer set for the highly sensitive amplification of most clinically relevant HPV genotypes. The assay covers all currently known high-risk HPV genotypes and probable high-risk HPV genotypes (16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73, 82) as well as a number of low-risk HPV genotypes (6, 11, 40, 43, 44, 54, 70) and some additional types (69, 71, 74).

    * For Research Use Only. Not for use in diagnostic procedures.

  • One strip – one test for the detection of the genus Mycobacterium and 16 mycobacterial species.

    INNO-LiPA® MYCOBACTERIA v2 is a line probe assay for the simultaneous detection and identification of the genus Mycobacterium and 16 different mycobacterial species. The test is based on the nucleotide differences in the 16S-23S rRNA spacer region and can be performed starting from either liquid or solid culture.

    The following Mycobacterium species can be detected simultaneously: M. tuberculosis complex, M. kansasii, M. xenopi, M. gordonae, M. genavense, M. simiae, M. marinum and M. ulcerans, M. celatum, MAIS, M. avium, M. intracellulare, M. scrofulaceum, M. malmoense, M. haemophilum, M. chelonae complex, M. fortuitum complex, and M. smegmatis.

  • INNO-LiPA® CFTR is a multiparameter line probe assay, based on the reverse hybridization principle, for the simultaneous detection and identification of 8 large rearrangements and 6 mutations and their wild-type sequences in human whole blood, dried blood spots, and buccal brush samples. For the detection and identification of all ACMG mutations the INNO-LiPA® CFTR19 and INNO-LiPA™ CFTR17+Tn Update kits are both required to be tested (testing for 35 mutations, one polymorphism and three Tn variants).

    Well-defined study cohorts prove that large rearrangements in the CFTR gene account for 16-26% of unidentified CF alleles in various populations. Large rearrangements, of which large deletions are the most common type, have a high clinical relevance as they will always lead to a severe form of the disease in presence of another CF causing mutation. This strip contains mutations that have a significant frequency in Italy, Bulgaria, Turkey and Hispanic Countries.

  • The fourth dimension in HCV antibody testing. INNOTEST® HCV Ab IV is an enzyme immunoassay for the detection of antibodies to human hepatitis C virus (HCV) in human serum or plasma.

  • The INNOTEST® hTAU Ag is a solid-phase enzyme immunoassay for the quantitative determination of Tau protein in human cerebrospinal fluid (CSF). This assay measures the biomarker called total Tau, including the six isoforms (352 to 441 amino acids) from the brain.

    The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-6).

  • The INNOTEST® PHOSPHO-TAU(181P) is a solid-phase enzyme immunoassay for the quantitative determination of phosphorylated Tau (Phospho-Tau(181P)) in human cerebrospinal fluid (CSF).

    The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-5). The discrimination of AD from non-AD types of dementia such as dementia with Lewy Bodies may be further improved using the quantification of CSF-phospho-Tau(181) (6-7).

  • The INNOTEST® β-AMYLOID(1-42) is a solid-phase enzyme immunoassay for the quantitative determination of β-amyloid(1-42) in human cerebrospinal fluid (CSF).

    The combined use of CSF-Tau and CSF-β-amyloid(1-42) marker concentrations allows differentiation between Alzheimer’s disease (AD) and normal aging or other neurological diseases such as depression (1-6).